Answers are grounded in this paper and cite their sources.
Case report highlights delayed HIV-1 diagnosis in an infant following maternal therapy with LA-CAB/RPV, suggesting need for extended testing.
We report on a 4-month-old infant with delayed HIV-1 diagnosis after maternal antiretroviral therapy with long-acting injectable cabotegravir plus rilpivirine (LA-CAB/RPV) in the third trimester. Prolonged viral suppression in HIV-infected infants exposed to maternal LA-CAB/RPV may necessitate molecular testing beyond three months of age to exclude infection.
No takes yet. Share an insight, caveat, or question.
Feiterna‐Sperling et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: